Back to Search
Start Over
No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’?
- Source :
- Annals of the rheumatic diseases, 81(4), 466-468. BMJ Publishing Group
- Publication Year :
- 2021
- Publisher :
- BMJ, 2021.
-
Abstract
- The three monoclonal antibodies ustekinumab, guselkumab and risankizumab targeting the p 40 or the 19 subunit of interleukin -23 have now been approved for the indication psoriasis and the former two also for psoriatic arthritis (PsA). Ustekinumab and risankizumab have appeared ineffective in randomised controlled trials with patients with axial spondyloarthritis (axSpA), but post-hoc analyses of PsA trials have now suggested that they may improve back pain symptoms potentially induced by axial inflammation based on PsA. Here we argue that, based on the absence of efficacy in axSpA, this is unlikely and more probably due to generic, non-specific effects, which are not adequately covered by the tools developed for the assessment of inflammation in axSpA.
- Subjects :
- medicine.medical_specialty
antirheumatic agents
Immunology
Arthritis
Interleukin-23
General Biochemistry, Genetics and Molecular Biology
Psoriatic arthritis
Rheumatology
Physicians
Psoriasis
Internal medicine
Spondylarthritis
Ustekinumab
Interleukin 23
Humans
Immunology and Allergy
Medicine
Spondylitis, Ankylosing
Spondylitis
Randomized Controlled Trials as Topic
Inflammation
Risankizumab
business.industry
Arthritis, Psoriatic
spondylitis
medicine.disease
cytokines
ankylosing
Guselkumab
arthritis
biological therapy
psoriatic
business
Axial Spondyloarthritis
medicine.drug
Subjects
Details
- ISSN :
- 14682060 and 00034967
- Volume :
- 81
- Database :
- OpenAIRE
- Journal :
- Annals of the Rheumatic Diseases
- Accession number :
- edsair.doi.dedup.....c7c8b795df6c0b668b0126b82ed78381